- Home
- XRTX
as 12-18-2024 10:02am EST
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
| Founded: | 2011 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.1M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 16.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.09 - $7.00 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest XORTX Therapeutics Inc. News
XRTX Breaking Stock News: Dive into XRTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
XORTX Announces Presentation at the Rare and Genetic Disease Summit
GlobeNewswire
2 months ago
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024
GlobeNewswire
2 months ago
XORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
2 months ago
XORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
2 months ago
XORTX Initiates Precision Medicine Program
GlobeNewswire
3 months ago
XORTX Announces Results of Annual and Special Meeting of Shareholders
GlobeNewswire
3 months ago
XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A
GlobeNewswire
3 months ago
XORTX Reminds Shareholders of Voting Deadline for Upcoming Annual and Special Meeting of Shareholders
Compare XRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XRTX XORTX Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.